India’s Supreme Court urges broader medicine price controls beyond cancer drugs2026-10-13The Supreme Court asked why the Centre’s proposed 30% trade-margin cap for specified cancer drugs could not be extended to other medicines and medical devices.The justices cited a saline drip line costing about ₹11 but selling for ₹270, and a cardiac stent with a retailer price of ₹5,000 and an MRP of ₹25,000.The court asked the Centre to work out a broader approach to medicine price controls by October 27, when the case is due to be heard again.The Centre argued that wider intervention could disrupt the market and medicine availability, while the court said ensuring patients can access medicines is the government’s responsibility.'Why only cancer drugs?': SC questions Centre on trade margin cap, seeks wider price regulation (Mint)Centre caps trade margin of anti-cancer drugs at 30%; SC asks why not other medicines - The Tribune (The Tribune)SC questions why 3 per cent trade margin cap on anti-cancer drugs cannot cover all medicines (The New Indian Express)SC to government: Cap prices of non-patented medicines (The Times of India)SC asks govt to broaden inflated pricing review beyond oncology (The Economic Times)Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicines (The Economic Times)कैंसर की दवाओं पर 30% से ज्यादा मुनाफे पर रोक: सुप्रीम कोर्ट ने पूछा- दूसरी दवाइयों की कीमत पर कंट्रोल क्यो... (Dainik Bhaskar)'11 रुपये की ड्रिप 270 में क्यों?', दवाओं के भारी-भरकम मुनाफे पर सुप्रीम कोर्ट सख्त - india caps cancer drug margins at 30 percent sc demands broader control (Dainik Jagran)క్యాన్సరేతర ఔషధాల ధరలపైనా పరిమితి ఎందుకు విధించరు? (Eenadu)